Login Join us
Benefits Strategy

Ketamine and Psychedelics as a Treatment for Mental Health Conditions: Employer FAQs

Interest in ketamine and other psychedelics for treatment-resistant depression and additional psychiatric disorders has grown in recent years, driven by new research on their potential clinical benefits, but there are several considerations for employers that should be top of mind.

icon_featured_hand

January 25, 2024

More in Benefits Strategy

TABLE OF CONTENTS

  1. Are psychedelics currently FDA approved for mental health treatment?
  2. Is psychedelic- or ketamine-assisted therapy covered under standard benefit plans?
  3. What conditions are treated with ketamine and psychedelics?
  4. How are ketamine and psychedelics administered?
  5. How are health care providers involved in the administration of ketamine- and psychedelic-assisted therapy? Do they need to be credentialed?
  6. How long does treatment take? And does it need to be repeated?
  7. Are psychedelics effective?
  8. Are there risks associated with ketamine and psychedelics?
  9. Do people receiving psychedelics need to take medical leave while in treatment?
  10. How much do psychedelics, ketamine and wraparound services like talk therapy cost?
  11. What legal, cultural or public relations issues may impact coverage of psychedelics?